Pancreas cancer and the role of soluble immunoglobulin-like transcript 3 (ILT3)

Journal of the Pancreas

Volumn 8, Issue 6, 2007, Pages 697-703

  Cortesini, Raffaello ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

LILRB4 protein, human; Macrophages; Pancreatic neoplasms; Receptors, cell surface; T lymphocytes, regulatory; Tumor escape

Indexed keywords

CANCER VACCINE; CD68 ANTIGEN; CELL PROTEIN; IMMUNOGLOBULIN LIKE TRANSCRIPT 3; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALTERNATIVE RNA SPLICING; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG TREATMENT FAILURE; EDITORIAL; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; LYMPH NODE BIOPSY; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE FUNCTION; MIXED LYMPHOCYTE CULTURE; NONHUMAN; PANCREAS BIOPSY; PANCREAS CANCER; PANCREAS CARCINOMA; PLASMAPHERESIS; PROGNOSIS; PROTEIN DEPLETION; PROTEIN SYNTHESIS; SCID MOUSE; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE;

ANTIBODIES, MONOCLONAL; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; HUMANS; IMMUNOSORBENT TECHNIQUES; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; PLASMAPHERESIS; PROGNOSIS; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES, REGULATORY;

EID: 36749067188     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Editorial

References (43)

1. Van Cutsem E, Verslype C, Grusenmeyer PA. Lessons learned in the management of advanced pancreatic cancer. J Clin Oncol 2007; 25:1949-52.
2. Saif MW. Pancreatic cancer: is this bleak landscape finally changing?. JOP. J Pancreas (Online) 2007; 8:365-73.
3. Plate JE, Harris JE. Immunobiotherapy directed against mutated and aberrantly expressed gene products in pancreas cancer. J Cell Biochern 2005; 94:1069-77.
4. Vlad G, Cortesini R, Suciu-Foca N. License to heal: bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC. J Immunol 2005; 174:5907-14.
5. Figdor GC, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10:475-80.
6. Shu S, Cochran AJ, Huang RR, Morton DL, Maecker HT. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Cancer Metastasis Rev 2006; 25:233-42.
7. Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005; 11: 1230-7.
8. Rosemberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-15.
9. Massague J. G1 cell-cycle control and cancer. Nature 2004: 432:298-306.
10. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Inummol 2002; 3:999-1005.
11. Dunn GP, Old IJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21:137-48.
12. Pinzon-Charry A, Maxwell T, Lopez JA. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 2005; 83:451-61.
13. Manavalan JS, Rossi PC, Vlad G, Piazza F, Yarilina A, Cortesini R, et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Inummol 2003; 11:245-58.
14. Cella M, Dohring C, Samaridis J, Dessing M, Brockhaus M, Lanzavecchia A, et al. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, andT dendritic cells involved in antigen processing. J Exp Med 1997; 185:1743-51.
15. Kim-Schulze S, Scotto L, Vlad G, Piazza F, Lin H, Liu Z, et al. Recombinant Ig-like transcript 3-Fe modulates T cell responses via induction of Th anergy and differentiation of CD8+ T suppressor cells. J Immunol 2006; 176:2790-8.
16. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6:295-307.
17. Shevach EM. Fatal attraction: tumors beckon regulatory T cells. Nat Med 2004; 10:900-L
18. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9.
19. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108:804-11.
20. Suciu-Foca N, Feirt N, Zhang QY, Vlad G, Liu Z, Lin H, et al. Soluble Ig-like transcript 3 inhibit tumor allograft rejection in humanized SCID mice and T cell responses incancer patients. J Immunol 2007; 178:7432-41.
21. Suciu-Foca N, Buda J, McManus J, Thiem T, Reemtsma K. Impaired responsiveness of lymphocytes and serum-inhibitory factors in patients with cancer. Cancer Res 1973; 33:2373-7.
22. Wanebo HJ, Blackinton D, Kouttab N, Mehta S. Contribution of serum inhibitory factors and immune cellular defects to the depressed cell-mediated immunity in patients with head and neck cancer. Am J Surg 1993; 166:389-94.
23. Bohlen H, Kessler M, Sextro M, Diehl V, Tesch H. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol 2000; 79:110-3.
24. Chang CC, Ferrone S. NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance. Semin Cancer Biol 2006; 16:383-92.
25. Coudert JD, Held W. The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol 2006; 16:33343.
26. Groh V, Smythe K, Dai Z, Spies T. Fas-ligandmediated paracrine T cellregulation by the receptor NKG2D in tumor immunity. Nat Immunol. 2006; 7:755-62.
27. Nomura T, Sakaguchi S. Naturally arising CD25+CD4+ regulatory T cells in tumor immunity. Curr Top Microbiol Inummol 2005; 293:287-302.
28. Liu Z, Tugulei S, Cortesini R, Suciu-Foca N. Specific suppression of T helper alloreactivity by, allo-MHC class I-restricted CD8+CD28- T cells. Int Immunol 1998; 10:775-83.
29. Chang CC, Ciubotariu. R, Manavalan JS, Yuan J, Colovai AI, Piazza F, et al. Tolerization of dendritic cells by Ts cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002; 3:237-43.
30. Rifa'i M, Kawamoto Y, Nakashima I, Suzuki H. Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis. J Exp Med 2004; 200:1123-34.
31. Gilliet M, Liu YJ. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002; 195:695-704.
32. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5:1219-26.
33. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193:233-8.
34. Steinbrink Y, Graulich E, Kubsch S, Knop J, Enk AH. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002; 99:2468-76.
35. Kapp JA, Honjo & Kapp LM, Xu X, Cozier A, Bucy RP. TCR transgenic CD8+ T cells activated in the presence of TGF(beta) express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection. Int Immunol 2006; 18:1549-62.
36. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F, et at. Effector fimction of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004; 64:2865-73.
37. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5:677-85.
38. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23:549-55.
39. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3:23-35.
40. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram. P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203:871-81.
41. Zeni E, Mazzetti L, Miotto D, Lo Cascio N, Maestrelli P, Querzoli P, et al. Macrophage expression of IL-10 is a prognostic factor in non-small cell lung cancer. Eur Respir J 2007; May 30.
42. Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006; 66:2520-6.
43. Nielsen C, Ohm-Laursen L, Barington T. Husby S, Lillevang ST. Alternative splice variants of the human PD-1 gene. Cell Immunolol 2005; 235:109-16.